Ottobock reports on a strong 2025 performance thanks to new products and acquisitions
Mobility equipment specialist Ottobock has announced that it has generated revenues of £1,073.3 million in the first nine months of financial year 2025, compared with the first nine months of 2024 at £1,025.8 million.
For the core business, this translates into revenue growth of 13.6 per cent to £1,019.3 million, in comparison to the first nine months of 2024 at £898.4 million. Organic core growth before effects from currency and portfolio changes amounted to 11.5 per cent.
Ottobock says new product launches and positive developments in reimbursement, seven successful acquisitions as well as strategic investments contributed to the favourable development.
Core business generated growth of 29.4 per cent to £247.6 million, compared with the first nine months of 2024 at £191.1 million.
Adjusted net income rose by 81.3 per cent to £104.5 million, compared with the first nine months of 2024 at £57.7 million. Free cash flow increased by 55.0 per cent to £152.1 million compared with the first nine months of 2024 at £98.5 million.
Oliver Jakobi, CEO of Ottobock, commented: “We continue on our profitable growth path – the combination of innovative products, targeted acquisitions and strategic investments in start-ups such as Phantom Neuro, Bionic Skins or Musclemetrix creates the basis for the next chapter in human-machine interface. Our innovative strength remains the key growth driver – the successful IPO now allows us to initiate the next phase of growth.”
The core business in the EMEA segment developed positively in the first nine months of the year. Segment core revenue increased by 13.2 per cent to £729.8 million, compared with the first nine months of 2024 at £644.0 million. This was mainly driven by demand for new products.
Based on the positive business performance in the first nine months of the current year, Ottobock specifies its full-year guidance for the group.
Core business is expected to grow in the upper half of 10 per cent – 13 per cent, including mergers and acquisitions (M&A) activities.
Organic core revenue growth is expected in the upper half of nine per cent–12 per cent. Underlying Core EBITDA margin is confirmed between 25 per cent–26 per cent.
The core business encompasses the product categories Products and Components (B2B) and Patient Care (B2C). The Ottobock Group comprises the core and non-core business; the latter includes subsidiaries or units planned for divestiture or closure within 18 months.
Motus Medical joined Ottobock in becoming a supplier of a revolutionary active e-mobility device which promises to transform the way the user moves.
